Canada has had a long-standing historical relevance when it comes to Neuroscience Brain Sciences and SR&ED eligible research activities. From the historical Montreal Neurological Institute and the pioneering research in neurosurgery by Dr. Wilder Penfield. The county continues to emerge as a leader in the neurosciences. From brain imaging, mental health innovation, and neurotechnology commercialization, Canada has consistently played a central role in advancing our understanding of the brain.
Canada’s neuroscience and neurotechnology scene is now moving from lab curiosity to commercial reality. Founders are building everything from brain-computer interfaces (BCIs) and neuromodulation devices, to AI-assisted diagnostics for concussion, epilepsy, Parkinson’s and mental-health care.
This incredible momentum is helped by a uniquely Canadian advantage, that is, the Scientific Research & Experimental Development (SR&ED) tax incentive; a program meant to offset the cost and risk of true R&D. For brain-tech startups facing long clinical timelines and complex regulatory pathways, SRED often becomes the financial backbone that turns high-risk science into scalable companies.
Why brain technology and advancements map naturally to SR&ED
Neurotech ventures nearly always confront scientific or technological uncertainties. Decoding noisy biosignals (EEG/MEG), non-invasive precision in stimulation, implant durability and biocompatibility, biomarkers that generalize beyond small cohorts, real-time artifact rejection under movement; these all involve R&D efforts seeking to resolve fundamental scientific questions to which there are no answers as of yet.
Of course, work to resolve such uncertainties typically requires systematic investigation (i.e. hypotheses, controlled experiments, iterative prototypes/tests, and rigorous scientific/data-driven analysis). That is precisely the type of activity SR&ED supports. For eligible claimants, the SR&ED credit provides a tax deduction for R&D expenditures and an investment tax credit (ITC) that can reduce taxes payable (or be refundable).
Such a program providing refundable credits can create cash flow even prior to profitability such that the runway can be extended between rounds of R&D research or potentially de-risk preclinical and clinical milestones.
What “eligible work” looks like in brain tech
While each neurotechnology company would maintain a unique goal, there are recurring R&D patterns that frequently align neuroscience activities with SR&ED eligibility.
These activities often target scientific or technological uncertainties that one cannot solve with standard methods and therefore require structured experimentation. Some illustrative examples include:
- Neuroimaging Innovation: Experimenting with novel MRI acquisition sequences, developing motion-correction algorithms for fMRI in pediatric or ambulatory settings, or validating PET tracers for earlier detection of neurodegenerative biomarkers.
- Brain–Computer Interfaces (BCIs): Building adaptive decoding pipelines that can recalibrate in real time to user fatigue or electrode drift; testing hybrid BCIs that combine EEG with near-infrared spectroscopy (fNIRS); iteratively improving accuracy and latency of cursor control or robotic arm manipulation.
- Cognitive & Mental Health AI: Developing machine-learning models to detect early markers of Alzheimer’s or Parkinson’s disease from retinal scans, speech patterns, or digital phenotyping data.
- Rehabilitation & Neuroprosthetics: Developing exoskeleton control strategies powered by neural signals; testing closed-loop neurofeedback systems for stroke rehabilitation; running human-in-the-loop experiments to fine-tune signal thresholds and safety interlocks.
- Neuropharmacology & Neuromodulation: Designing drug-device combination systems (e.g., targeted neurostimulation paired with pharmacological delivery); running iterative experiments on stimulation parameters to reduce side effects in depression or epilepsy treatments; developing predictive models to personalize stimulation intensity or personalized drug delivery.
This is by no means an exhaustive list, but if the work targets an uncertainty and proceeds through a documented program of experiment or analysis, it can often qualify, even when results are inconclusive! A null-result is still a result!
Bringing it together: An efficient path for brain tech
Neuroscience startups are pushing the frontier of human health and performance, tackling challenges that demand bold experimentation and sustained investment. Canada’s SR&ED program directly supports this neuroscience journey, providing critical financial incentives for the research and development activities that define the neurotech sector.
When combined with the country’s strong ecosystem of academic excellence, commercialization programs, and growing investor interest, SR&ED can help innovators move from concept to market with greater speed, stronger evidence, and less reliance on dilutionary funding.
Importantly, Canada’s leadership in responsible-innovation standards ensures that advancements in brain science are developed with ethics, safety, and societal benefit in mind.
With the right neuroscience SR&ED strategy, founders can turn cutting‑edge experiments into scalable companies.
At Leyton, we specialize in helping companies navigate this complex landscape, thereby capturing uncertainties, documenting experimental progress, and maximizing claim value.
If you’re architecting the future of brain tech, we’d love to help you turn your experiments into lasting impact.
